Back to Agenda
The View from the Top: What is the Future of Medical Writing?
Session Chair(s)
Robin Whitsell
President
Whitsell Innovations, Inc., United States
Senior regulatory writing leaders from top pharma companies will share a candid, strategic view of how medical/regulatory writing is evolving over the next 3–5 years. The panel will explore how technology (including AI and structured content), new regulatory pathways, and shifting operating models are redefining writer responsibilities, team structures, and the value writers bring to development programs. Attendees will leave with clear insights on future-ready skills and practical steps to position regulatory writing as a critical driver of regulatory and clinical success.
Learning Objective : Describe leadership-level forecasts for the medical/regulatory writing function over the next 3–5 years, including key forces driving change; Identify how top pharma organizations are redefining the role and value of regulatory writers; Explain the implications of technology adoption on writer responsibilities, quality oversight, and team structures.
Speaker(s)
Panelist
Elizabeth Brown, MS, PMP
Merck & Co., Inc., United States
Executive Director, Clinical & Regulatory Strategic Communications
Panelist
Krista Crenshaw, MS
Alcon, United States
Director, Clinical Writing & QC
Panelist
Nancy Tam, MS
Pfizer, United States
Vice President and Head of Medical Writing
Panelist
Joanne Hilton, MBA
GlaxoSmithKline, United Kingdom
VP, Global Medical Writing
Have an account?